ABSTRACT
INTRODUCTION
A survey of World Health Organization (WHO) reveals that 9.2 million new tubercle bacillus (TB) or Mycobacterium tuberculosis (Mtb) infection cases are recorded globally, of which about 3 million infections from Africa, a 3 million from Southeast Asia and about a 2 million from Western Pacific region are reported. Furthermore, India and China are reported to have the largest total numbers of new cases, while South Africa had the highest rate of new cases.
1,2 Despite the use of the combination-chemotherapy with 4 first-line drugs, isoniazid, pyrazinamide, ethambutol and rifampicin, along with selective second-line drugs in the regular therapy and in the 'directly observed treatment shortcourse programme', mortality figure is consistently increasing in African and South Asian countries. 3 Furthermore, several second-line drugs, chemotherapeutics (ethionamide, thiacetazone, prothionamide and clofazimine), antibiotics (amikacin, kanamycin, debekacin, cycloserine, capreomycin and viomycin) are not well tolerated. 3 Moreover, multidrug resistant (MDR), resistance to at least isoniazid and rifampicin, extensively drug-resistant (XDR) and extre mely drug-resistant (XXDR) and ghoulish totally drug-resistant (TDR) tuberculosis cases described as resistant to resistant 'all first-line drugs and second-line drugs' TB strains have emerged, rendering the present module of chemotherapy ineffective at several areas. [4] [5] [6] Mainly, Mtb developed resistance to pyrazinamide with alteration(s) in cell wall synthesis. 7, 8 In this scenario, the development of a novel well-tolerated and emulating anti-mycobacterial agent, for the control of MDR, XDR or TDR Mtb, is a dire necessity. Peptidoglycan layer is the major component of Mtb bacterial cell wall providing shape and rigidity, as in eubacteria. It is a homogeneous polymer consisting of sugar and amino acid polymers, N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), crosslinked by trans-peptide bridges, lying exterior to the plasma membrane. The biosynthesis of peptidoglycan layer is catalysed by enzymes, GlmS, GlmM, GlmU, MurA, MurB, MurC, MurD, MurE and MurF, at several coordinated cytoplasmic and periplasmicsteps (Table 1) . 9, 10 In the cytoplasmic step, the synthesis of UDP-MurNAc from UDP-GlcNAc is mediated by MurA ligase (UDP-N-acetylglucosamine 1-carboxyvinyl transferase), which was used as a suitable target for the drug development attempt. [9] [10] [11] [12] Previously for drug development, to address drug resistant strains of the Gram-positive bacterium, Enterococcus faecalis as well as, of M. leprae, Mur ligases were shown as target enzymes in molecular docking attempts. 13, 14 Obviously, an in silico computation would help locating a suitable control agent without the hit-andmiss method, which is often followed in drug targeting attempts; in vivo attempts would follow by apothecary, after being suitably indicated by computational work. Since, no molecular docking work using any Mur ligase is reported for drug targeting Mtb, this work describes screening of 13 cyano-compounds as possible antimycobacterial agents. As it is, cyanobacteria constitute a unique group of photosynthetic prokaryotes growing in soil, inland and marine waters. Several bioactive cyanocompounds have been isolated and characterized, which could be used in drug discovery, for example, against cancer. 15 Here only 13 cyano-compounds were selected in docking attempts against Mtb MurA enzyme from earlier reports on antimycobacterial activity. [16] [17] [18] Nuclear magnetic resonance (NMR) or X-ray crystallography structure of Mtb MurA enzyme is not yet reported and that being unavailable in Protein Data Bank (PDB), in this work a homology model of Mtb MurA is generated and validated by a Ramachandran plot. It was further used as the drug-target in docking study with cyano-compounds, in comparison to 4 firstline anti-tuberculosis drugs and antibiotic, isoniazid, pyrazinamide, ethambutol and rifampicin, individually. Toxicity study is an essential corollary, before the pre-clinical stage of a recommended chemical, which is predicted suitable as drugable agent computationally. It is anticipated that the most effective cyano-compound determined herein could be used as new anti-tuberculosis drug.
MATERIALS AND METHODS

Homology modeling of M. tuberculosis MurA ligase
The amino acid sequence of Mtb MurA ligase was retrieved from the UniProtKB database (http://www. uniprot.org/). The 3-Dstructure of MurA ligase was modelled using the MurA of the bacterium, Listeria monocytogenes as the suitable template, with the help of tools, BLASTp (http://blast.ncbi.nlm.nih.gov/Blast), Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2), CS-BLAST (http://toolkit.tuebingen.mpg.de/cs_blast), I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) and ProSA-web (https://prosa.services.came.sbg.ac.at/) were too used for checking the reliability of the generated homology model of MurA ligase. Furthermore, the model was subjected to energy minimization by the Swiss-Pdb Viewer (http://spdbv.vital-it.ch/) software, for maintaining its stability before a docking attempt.
Molecular docking
In molecular docking, the possibility of blocking the target protein/receptor, involved in a particular disease by a ligand in inhibiting its active site(s), is assessed. A ligand gets attached onto the larger molecule, the receptor in a specific orientation with generation of an energy value, the docking score (kcal/mol.), specific for the particular protein-ligand complex. The most effective ligand is selected from the minimum docking score of a complex, among several ligands and similar receptor complexes. Structures of 13 cyano-compounds and 4 on-going anti-tuberculosis drugs were retrieved from the chemical database, PubChem (https://pubchem.ncbi.nlm.nih. gov/search/ search.cgi) and the DrugBank (http:// www.drugbank.ca/), respectively, for docking study. The retrieved structures of compounds/ drugs were saved into dot mol or '.mol' and dot pdb or '.pdb' file formats for use in molecular docking, which were done by using AutoDock Vina and PatchDock softwares, as reported. 20, 21 Docking studies with receptor enzyme MurA and individual ligands as cyano-compounds and 4 first-line anti-tuberculosis drugs were attempted. PyMOL (https://www.pymol.org/) and LigPlot (http://www.ebi.ac.uk/thornton-srv/software/ LIG-PLOT/#) softwares were used to visualize the generated 3-D model of MurA ligase and its interactions with ligands in docking study.
In silico toxicity prediction
The in silico toxicity prediction remains an advanced approach to rationalize the process of preclinical drug development, by reducing the associated time and costs on animal experiments. Here, the ProTox (http://tox. charite.de/tox) web server was used in evaluating LD 50 values of oral toxicity and the toxicity class of the used cyano-compounds. Additionally, the chemoinformatic tool LAZAR (Lazy Structure-Activity Relationships) (http://lazar.in-silico.de/predict) was used for assessing carcinogenic and mutagenic natures, along with assessing possible LC 50 value and the daily recommended dose of each cyano-compound used herein and anti-tuberculosis drugs. LAZAR provides 85 % mutagenicity and carcinogenicity up to 95% predictions for a query compound. Moreover, recommended daily dose of a query compound, herein a cyano-compound is calculated by comparison with data of available training set or known drugs approved by Food and drug administration.
RESULTS
Homology modeling of M. tuberculosis MurA ligase
After retrieval of target sequence of Mtb MurA ligase, 6 bioinformatics tools were used to find out the suitable template for modeling a 3-D structure. Based on the higher level of sequence similarity and identity, the structure of L. monocytogenes MurA ligase was selected as the suitable template with 48 % identity long with query coverage at 99 % for the homology modeling. The template modeling or TM score of MurA was 0.97 obtained through the TM-align programme of I-TASSER. The TM score was seen lying between 0.0 and 1.0 (and is > 0.5), which signifies that the MurA structure and selected template were in the same fold. The secondary structure of MurA ligase was predicted as 38.52 % helix, 19.62 % extended strand, 9.57 % beta-turn and 32.30 % random coil, by the SOPMA tool, which supported the stability of the protein due to the presence of indicated high percentage of helix. The generated homology model as 3-D structure of MurA ligaseof M. tuberculosis with helix, sheet and loop regions in three different colors is presented by PyMOL software (Figure 1) .The predicted molecular weight of MurA is 44063.5 kd, theoretical isoelectric point is 5.30 and the instability index is 28.49 (<40). As a result, instability index value and a higher proportion of the peptide as helix indicated that the protein is more stable in nature, determined by the ProtParam tool. In total numbers of negative charged residues are 49 % and the positive charged residues are 34 %, which indicated the MurA enzyme as acidic in nature.
Model validation
The Ramachandran plot statistics indicated that, 98.1 % residues were in the most favored region, 1.2 % residues were in allowed region and only 0.7 % residues were in the disallowed region (Figure 2) . Thus, the generated model of MurA was geometrically and stereo-chemically acceptable. Further, knowledge-based energy curves were generated for the target with Z-score values (MurA Z-score: -9.95), and for the template (3R38 Z-score: -10.92) by using ProSA-web (Supplementary Figure 1) . The Z-score and energy curve also indicated that the MurA model was within the Z-score range of experimentally determined NMR solved protein structure; and the Z-score of template was less different to the modeled MurA structure; ProSA-web confirmed the quality and consistency of the model that is acceptable. Data regarding the validation of the generated MurA model was validated.
Molecular docking
Thirteen cyano-compounds and 4 anti-tuberculosis drugs were docked individually against generated target, the Mtb MurA enzyme. Effective docking score values of 4 anti-tuberculosis drugs are as given against each (kcal/mol), -9.173 (rifampicin) > -7.865 (ethambutol) > -7.568 (isoniazid) > -6.981 (pyrazinamide) ( Table 2) . Among cyano-compounds, pitipeptolides F with docking score value, -13.765 was the most effective cyano-compound against Mtb MurA enzyme. Effective docking score values of 13 cyano-compounds are as given against each (kcal/mol): -13.765 (pitipeptolides F) Continued... (110) and ambiguine A isonitrile (60) ( Table 3 ; Suppl. Fig. 2 ). Among cyano-compounds and 4 anti-TB drugs, ambiguine A isonitrile, ambiguine K isonitrile, ambiguine M isonitrile, fischambiguine B, hapalindole A, pitipeptolides A, pitipeptolides B, pitipeptolides C, pitipeptolides D, pitipeptolides E, pitipeptolides F and isoniazid are in class III of toxicity compounds (LD 50 value with 50 ≤ 300 mg/kg, and increase in the toxicity class is marked by decreased toxic effects); and eucapsitrione, scytoscalarol, ethambutol and pyrazinamide are in class IV of toxicity compounds (LD 50 would be 300 ≤ 2000 mg/kg in this class); and only rifampicin is in class V toxicity compound (LD 50 would be 2000 ≤ 5000 mg/kg in this class) (Table 3) . Moreover, isoniazid and 11 cyano-compounds would be in class III toxic compound, but none of the later is carcinogenic. Thus, in comparison to isoniazid, LD 50 values of most cyano-compounds are less toxic; and thus those could be promoted as drugs due to lesser levels of toxicity (Table 3 ). According to LAZAR tool,used13 cyanocompounds and the rest of the 3 anti-tuberculosis drugs are arranged according to fish toxicity (in decreasing order of LC 50 value): pitipeptolides C, pitipeptolides A, pitipeptolides E, pitipeptolides F, pitipeptolides B, pitipeptolides D,ambiguine M isonitrile, fischambiguine B, rifampicin, ambiguine A isonitrile, hapalindole A, and ambiguine K isonitrile (Table 3 , Supplementary Figure 3) . And the rest 4 compounds, eucapsitrione, scytoscalarol, ethambutol and pyrazinamide were not predicted any bio-toxicity by the toxicity analyzer tool, LAZAR. Among 13 cyano-compounds, eucapsitrione is mutagenic and scytoscalarol is carcinogenic in nature. Here, isoniazid has the highest LC 50 value around 0.7 mmol against fathead minnow fish in comparison to other anti-TB drugs and the used cyano-compounds, but it has carcinogenic and mutagenic activity as indicated by the computational prediction (Table 3) . Moreover, cited cyano-compounds could be promoted as new anti-TB agents based on findings of molecular docking, LD 50 , LC 50 and toxicity class level.
DISCUSSION
Using computational tools, effective-most cyanocompounds, pitipeptolides F and pitipeptolides D were selected and used as alterative/ complementary agents against recently reported drug-resistant strains of M. tuberculosis. Computation biology is a system of advanced tools by which, a putative drug target is identified, rather predicted against the 3-D structure of a key target protein of a disease, which may be even generated by homology modeling, as here done for Mtb MurA, using the L. monocytogenes MurA structure as the template. Indeed in molecular docking, the target enzyme is blocked by the ligand that would be the probable future drug. Indeed, cyano-compounds from the archaic bacterial group are known to be unique compounds with several therapeutic activities ─ antibacterial, 16 ,25 antifungal 26,27 and anticancer efficacies.
15,28
This work computationally describes that two cyanocompounds, pitipeptolides F and D as the most effective antimycobacterial agents, in comparison to the presently used individual first-line anti-TB drugs. The in silico attempt of prediction of bio-activity of cyanocompounds included toxicity predictions with fish and mouse models herein. Moreover, isoniazid has been experimentally proved as carcinogenic in vivo mouse model too, 29 corroborating the in silico prediction presented here. During a drug development cascade for a disease, screening of a large number of characterized lead compounds are done in pharmacology and medicinal chemistry. But a compound to be designated as drug has to pass through the first stage of pre-clinical trial to four subsequent stages of clinical trials. As it is known, drug candidates entering clinical trials have been estimated having an 8 % chance of becoming marketed drugs with about a 20 % chance of failure due to high levels of host toxicity. 30 Blithely, modern computational predictions on drugable compounds have advantages in the drug development cascades, of saving the time in the in vitro and tiresome in vivo experiments, which are mandatory for the computationally recommended specific chemical intended as a future drug; nevertheless, animal trials are the essential corollary work in drug development.
CONCLUSION
The putative drug target, MurA enzyme of Mtb was generated by homology modeling and Ramachandran plot statistics proved that the generated MurA model was geometrically and stereo chemically acceptable. Molecular docking attempts could help locating comparatively more effective agents against the target enzyme MurA than the presently used first-line drugs and antibiotics in TB-chemotherapy. Indeed, cyanobacteria possess unique secondary metabolites with antimycobacterial potency evaluated by docking studies, and the indicated compounds are less toxic than isoniazid. Both molecular docking and toxicity studies indicated that two cyano-compounds, pitipeptolides F and D could be promoted as the effective agents against M. tuberculosis.
